SCHEMBL2350657

SCHEMBL2350657

Cc1nnc(Cl)c(-c2ccc(F)cc2F)c1-c1ccc(Cl)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
NPC1 O15118 2/20 0.36
TP53 P04637 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
CNR1 P21554 1/20 0.36
TSHR P16473 1/20 0.36
HSD17B10 Q99714 1/20 0.36
KDM4E B2RXH2 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA5 P31644 1/20 0.36
GABRA3 P34903 1/20 0.36
THRB P10828 1/20 0.36
LMNA P02545 1/20 0.35
HSD11B1 P28845 1/20 0.35
PSD A5PKW4 2/20 0.34
PTGS2 P35354 1/20 0.34
ADORA2A P29274 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13069543 0.93 RAB9A (0.40) RAB9AMEN1KMT2ANPC1TP53
SCHEMBL13102589 0.92 ADORA2A (0.36) RAB9AMEN1KMT2ANPC1SMN1; SMN2
SCHEMBL2348149 0.90 RAB9A (0.38) RAB9AMEN1KMT2ANPC1TP53
SCHEMBL2353562 0.86 KCNQ3 (0.38) RAB9AMEN1KMT2ANPC1TP53
SCHEMBL2351120 0.85 MEN1 (0.34) RAB9AMEN1KMT2ANPC1TP53
SCHEMBL1869939 0.84 RAB9A (0.36) RAB9AMEN1KMT2ANPC1TP53
SCHEMBL2348260 0.83 APEX1 (0.45) RAB9AKMT2ANPC1SMN1; SMN2TSHR
SCHEMBL2356139 0.81 MEN1 (0.36) RAB9AMEN1KMT2ANPC1TP53
SCHEMBL2354401 0.80 MEN1 (0.35) RAB9AMEN1KMT2ANPC1TP53
SCHEMBL895850 0.80 GABRG2 (0.41) RAB9AMEN1KMT2AKDM4EGABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3219207-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES The Trustees Of The University Of Pennsylvania (US) 2017-09-20 EP disclosed
US-20170173016-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES NIH - DEITR 2017-06-22 US disclosed
US-9649317-B2 Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2017-05-16 US disclosed
US-20150224105-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES NIH - DEITR 2015-08-13 US disclosed
WO-2014047257-A2 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2014-03-27 WO disclosed
US-8008512-B2 Pyridazine compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-30 US disclosed
US-8008512-B2 Pyridazine compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-30 US disclosed
US-8008512-B2 Pyridazine compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-30 US disclosed
US-20100273804-A1 PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER SYNGENTA CROP PROTECTION, INC. (US) 2010-10-28 US disclosed
US-20100144674-A1 PYRIDAZINE DERIVATIVES SYNGENTA CROP PROTECTION, INC. (US) 2010-06-10 US disclosed
US-20090281337-A1 Pyridazine compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED 2009-11-12 US disclosed
US-7569518-B2 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-08-04 US disclosed
US-7569518-B2 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-08-04 US disclosed
US-7569518-B2 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-08-04 US disclosed
EP-1767529-B1 PYRIDAZINE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2009-05-06 EP disclosed
US-20090023687-A1 Method for Controlling Phytopathogenic Organisms SYNGENTA CROP PROTECTION, INC. (US) 2009-01-22 US disclosed
US-20080194566-A1 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-08-14 US disclosed
US-20080194566-A1 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-08-14 US disclosed
US-20080194566-A1 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-08-14 US disclosed
EP-1767529-A1 PYRIDAZINE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2007-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170173016-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES MAPT, PRNP, PSEN2 RAB9A 3442/4885MEN1 3639/4885KMT2A 1668/4885
US-20080194566-A1 Pyridazine Compound and Use Thereof PLPBP, PNPO, CYP4Z1 RAB9A 1013/4885MEN1 2346/4885KMT2A 2463/4885
US-20150224105-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES MAPT, SYNJ1, PARK7 RAB9A 2718/4885MEN1 4395/4885KMT2A 2523/4885
US-20090281337-A1 Pyridazine compound and use thereof PLPBP, PNPO, CYP4Z1 RAB9A 1013/4885MEN1 2346/4885KMT2A 2463/4885
US-20090023687-A1 Method for Controlling Phytopathogenic Organisms GRHPR, GUSB, GLO1 RAB9A 3863/4885MEN1 3140/4885KMT2A 2342/4885
US-20100144674-A1 PYRIDAZINE DERIVATIVES C3AR1, C1S, CBR3 RAB9A 3381/4885MEN1 4260/4885KMT2A 3327/4885
US-20100273804-A1 PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER C3AR1, CBR3, C1S RAB9A 1704/4885MEN1 185/4885KMT2A 3241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.